Genome Web Breaking News
- InterVenn Biosciences Closes $201M Series C Round
- Abcam to Acquire Life Science Research Tool Firm BioVision for $340M
- Lunaphore Technologies, University of Bern Partner on Colorectal Cancer Study
- People in the News: New Appointments at Biocept, Novacyt, Centogene, Illumina, More
- Interfering With Invasive Mussels
Stat
- STAT+: Pharmalittle: Pfizer and Moderna raise Covid-19 vaccine prices for Europe; FDA to speed full approval of Pfizer shot
- No new monkeypox cases reported after health officials monitor hundreds
- Opinion: STAT+: Stifling biopharma mergers would kill the innovation economy that generates new therapies
- Opinion: ‘Here be dragons’: Long-term survivors like me can help map the boundaries of cancer
- ‘A mini-engineering feat’: High-tech headphones drown out the scary noises inside an MRI
NYT science news
- A Brain Drain Among Government Scientists Bogs Down Biden’s Climate Ambitions
- ‘X’ Marks the Spot: Officials Map a Route Out of the Pandemic
- With Undersea Robots, an Air Force Navigator Lost Since 1967 Is Found
- Stranded Killer Whale Survives With Help of Good Samaritans
- In South Africa, Poachers Now Traffic in Tiny Succulent Plants
Fierce Biotech
- Abbott debuts smart monitor that fishes for abnormal heart rhythms in the data stream
- Moderna lands option on Autolus binders to fuel oncology plans
- Zentera Therapeutics eyes 2022 Hong Kong listing, but first, a $75M series B to support oncology assets
- T-knife Therapeutics bags $110M to sharpen solid tumor cell therapy push into the clinic
- AbbVie plans to move next-gen Aduhelm hopeful for Alzheimer's into the clinic
Fierce Medical Devices
- Abbott debuts smart monitor that fishes for abnormal heart rhythms in the data stream
- Bioventus ponies up $518M for ultrasonic surgical device maker Misonix
- NuVasive nabs FDA clearance amid global rollout of all-in-one spine surgery platform
- Biofourmis nets FDA breakthrough label for digital heart failure treatment assistant
- Rakuten Medical rakes in $166M series D following drug-device combo's approval in Japan